Literature DB >> 29223641

Re-irradiation for Locally Recurrent Lung Cancer: Evidence, Risks and Benefits.

R Rulach1, G G Hanna2, K Franks3, J McAleese2, S Harrow4.   

Abstract

In spite of recent improvements in both the technical delivery of radiotherapy and systemic therapy in the treatment of non-small cell lung cancer, local recurrence rates after radiotherapy remain a significant challenge. In the setting of local relapse after radiotherapy, treatments such as surgical resection or radiofrequency ablation are often not appropriate owing to disease and patient factors. Re-irradiation may be a potential treatment option. This overview considers the published evidence and potential treatment strategies.
Copyright © 2017 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Lung cancer; radiotherapy; re-irradiation; retreatment

Mesh:

Year:  2017        PMID: 29223641     DOI: 10.1016/j.clon.2017.11.003

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  9 in total

1.  Definitive radiotherapy for hilar and/or mediastinal lymph node metastases after stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer: 5-year results.

Authors:  Yoshihiko Manabe; Yuta Shibamoto; Fumiya Baba; Takeshi Yanagi; Hiromitsu Iwata; Akifumi Miyakawa; Taro Murai; Katsuhiro Okuda
Journal:  Jpn J Radiol       Date:  2018-09-14       Impact factor: 2.374

Review 2.  Re-irradiation for intra-thoracic tumours and extra-thoracic breast cancer: dose accumulation, evaluation of efficacy and toxicity based on a literature review.

Authors:  Dorota Gabrys; Roland Kulik; Agnieszka Namysł-Kaletka
Journal:  Br J Radiol       Date:  2021-12-08       Impact factor: 3.629

3.  Second Re-irradiation: Clinical Examples of Worthwhile Treatment.

Authors:  Carsten Nieder; Rosalba Yobuta; Bård Mannsåker
Journal:  Cureus       Date:  2018-06-15

4.  The Special Medical Physics Consult Process for Reirradiation Patients.

Authors:  Kelly C Paradis; Charles Mayo; Dawn Owen; Daniel E Spratt; Jason Hearn; Benjamin Rosen; Rojano Kashani; Jean Moran; Daniel S Tatro; Whitney Beeler; Karen Vineberg; Dylan C Smith; Martha M Matuszak
Journal:  Adv Radiat Oncol       Date:  2019-06-08

Review 5.  Current status and future directions in unresectable stage III non-small cell lung cancer.

Authors:  Esperanza Arriola Arellano; Verónica Díaz Díaz; Joaquín José Cabrera Rodríguez
Journal:  J Clin Transl Res       Date:  2020-10-29

6.  An International Expert Survey on the Indications and Practice of Radical Thoracic Reirradiation for Non-Small Cell Lung Cancer.

Authors:  Robert Rulach; David Ball; Kevin L M Chua; Max Dahele; Dirk De Ruysscher; Kevin Franks; Daniel Gomez; Matthias Guckenberger; Gerard G Hanna; Alexander V Louie; Drew Moghanaki; David A Palma; Clive Peedell; Ahmed Salem; Shankar Siva; Gregory M M Videtic; Anthony J Chalmers; Stephen Harrow
Journal:  Adv Radiat Oncol       Date:  2021-01-20

7.  An algorithm for thoracic re-irradiation using biologically effective dose: a common language on how to treat in a "no-treat zone".

Authors:  Eric D Brooks; Xiaochun Wang; Brian De; Vivek Verma; Tyler D Williamson; Rachel Hunter; Abdallah S R Mohamed; Matthew S Ning; Xiaodong Zhang; Joe Y Chang
Journal:  Radiat Oncol       Date:  2022-01-06       Impact factor: 3.481

Review 8.  High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC.

Authors:  Brane Grambozov; Markus Stana; Bernhard Kaiser; Josef Karner; Sabine Gerum; Elvis Ruznic; Barbara Zellinger; Raphaela Moosbrugger; Michael Studnicka; Gerd Fastner; Felix Sedlmayer; Franz Zehentmayr
Journal:  Cancers (Basel)       Date:  2022-01-23       Impact factor: 6.639

9.  Re-Irradiation for Locally Recurrent Lung Cancer: A Single Center Retrospective Analysis.

Authors:  Brane Grambozov; Evelyn Nussdorfer; Julia Kaiser; Sabine Gerum; Gerd Fastner; Markus Stana; Christoph Gaisberger; Romana Wass; Michael Studnicka; Felix Sedlmayer; Franz Zehentmayr
Journal:  Curr Oncol       Date:  2021-05-13       Impact factor: 3.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.